查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1969452

Granisetron市场：按剂型、产品类型、应用、通路和最终用户划分－2026-2032年全球预测

Granisetron Market by Dosage Form, Product Type, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Granisetron市场价值将达到 79.5 亿美元，到 2026 年将成长到 85 亿美元，到 2032 年将达到 136.5 亿美元，复合年增长率为 8.03%。

主要市场统计数据
基准年 2025 79.5亿美元
预计年份：2026年 85亿美元
预测年份 2032 136.5亿美元
复合年增长率 (%) 8.03%

Granisetron的权威介绍：临床机制、製剂演变及其对现代止吐疗法的意义。

Granisetron是一种选择性5-HT3受体拮抗剂，广泛用于预防和治疗化疗、放疗及术后护理相关的噁心和呕吐。其临床效用源自于其作用机制，即抑制胃肠道和中枢神经系统中由5-羟色胺介导的呕吐讯号通路，使其成为一种重要的止吐药物，其耐受性和疗效对于患者的生活品质至关重要。随着时间的推移，製剂的改进和临床指南的更新，使得Granisetron的给药途径更加多样化，涵盖了从住院输液室到门诊手术和门诊肿瘤诊室等各种医疗环境。

不断发展的临床通讯协定、生产整合、更严格的监管以及分销创新正在重塑Granisetron的环境。

Granisetron的现状正受到临床、监管和供应等多方面因素复杂相互作用的影响，这些因素正在改变止吐治疗的格局。药物科学的进步正在创造以患者为中心的治疗选择，例如分散剂和口服製剂，从而降低了门诊治疗的门槛。同时，随着对多方面支持性治疗的日益重视，肿瘤科和手术全期专科的通讯协定标准化也在不断推进，这影响着处方模式和医疗服务提供者的用药清单。

2025 年关税调整对Granisetron采购、供应弹性和分销连续性的营运影响评估。

到了2025年，累积政策调整、关税调整和贸易措施相继出台，为全球药品供应链带来新的挑战，影响着Granisetron的供应状况和成本结构。跨境采购活性成分和最终剂型的生产商和经销商正在评估多层关税、复杂的海关程序以及潜在的报復性贸易措施的影响。这些变化促使企业重新审视筹资策略、合约条款和库存缓衝，以应对不断上涨的进口成本和海关延误风险。

详细的細項分析揭示了剂型、临床应用、通路、终端用户环境和产品类型如何影响Granisetron。

细分市场分析揭示了Granisetron的治疗和商业性效用如何受到製剂形式、临床应用、通路、终端用户环境和产品类型的影响。依剂型分类包括注射剂、口溶锭和一般片剂。对于注射剂，临床医生可以选择快速静脉大剂量投药或持续静脉输注，而片剂则方便门诊患者使用。依临床用途分类，格拉司琼可分为化疗引起的噁心呕吐、术后噁心呕吐和放疗引起的噁心呕吐。在化疗引起的噁心呕吐适应症中，区分急性期和延迟期会影响治疗方法的选择和联合治疗的确定。

本研究提供了医疗保健系统、监管差异和分销基础设施的区域概览，并分析了主要地区在获取Granisetron的差异。

区域趋势对Granisetron在不同医疗体系中的生产、监管和应用起着决定性作用。在美洲，成熟的肿瘤科和手术全期护理实践倾向于注射剂和口服剂型联合使用，而采购则倾向于在成本效益和无菌供应的连续性之间取得平衡。报销机制和医院处方笺流程会影响格拉司琼的采用率以及品牌药和非专利药之间的竞争程度，而集中采购协议则会对竞标结果产生显着影响。

从公司层级进行竞争和营运分析，重点关注製造能力、监管应对力和经销伙伴关係，这些因素决定了Granisetron市场的主导。

Granisetron市场的竞争格局反映了成熟药物研发公司、非专利生产商、无菌注射剂专业公司和分销机构之间的平衡。药物研发公司旨在提升品牌知名度和临床认可度，因此倾向于投资于实证医学研究和医疗专业人员培训，以巩固其市场地位。另一方面，非专利药生产商则优先考虑生产效率、快速合规和价格竞争力，以确保与医疗机构签订合约。专门从事无菌注射剂生产的契约製造组织（CMO）在确保供应连续性方面发挥着至关重要的作用，尤其是在需要受控环境和检验的无菌製程生产的静脉注射製剂方面。

为确保Granisetron的永续成功，提出切实可行的跨部门建议，以确保生产韧性、临床差异化和分销合作。

产业领导者应采取多管齐下的策略，整合临床、生产和商业策略，以确保永续的竞争优势。首先，应透过多地点合格评估、与专业无菌注射剂供应商建立策略合作伙伴关係以及製定正式的紧急应变计画来增强生产韧性，以应对原材料采购和物流中断。同时，加大对品质系统和法规遵循的投入，将降低供应中断风险，并保障所有剂型的产品品质。

采用稳健的混合方法研究途径，结合对临床医师的访谈、监管审查、药理学文献和供应链分析，确保了实际可靠性。

本报告的研究整合透过结合一手和二手研究、监管文件、药理学文献以及相关人员访谈，确保了其可靠性和实用性。一手研究包括对临床医生、医院药剂师、采购专家和生产专家的访谈，以了解操作实践、治疗偏好和供应链限制。这些定性研究结果透过同行评审的临床研究、产品专论和公开的监管文件进行三角检验，以检验临床定位和生产方面的考虑。

一份权威的综合分析报告，重点阐述了Granisetron的持续临床意义，以及生产、分销和循证应用方面的战略要求。

Granisetron以其清晰的作用机制和可满足多种临床需求的灵活剂型，仍是现代止吐疗法的基石。製剂创新、生产专业化和不断发展的通路相互作用，为生产商、供应商和经销商带来了机会和营运挑战。投资于强大的无菌生产能力、专注于从高价值临床应用案例中获取相关人员，并推广符合医院、诊所和门诊中心偏好的分销策略的偏好相关者，将更有利于维持供应的连续性并展现其临床价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：Granisetron市场（以剂型划分）

  • 注射药物
    • 静脉Bolus
    • 持续静脉输注
  • 口溶锭
  • 药片
    • 标准

第九章：Granisetron市场：依产品类型划分

  • 品牌商品
  • 学名药

第十章：Granisetron市场：依应用领域划分

  • 化疗引起的噁心和呕吐
    • 急性期
    • 后期
  • 术后噁心呕吐
  • 放射治疗引起的噁心和呕吐

第十一章Granisetron市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章Granisetron市场：依最终用户划分

  • 门诊手术中心
  • 诊所
  • 医院

第十三章Granisetron市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章Granisetron市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章Granisetron市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国Granisetron市场

第十七章：中国Granisetron市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
Product Code: MRR-535C62918923

The Granisetron Market was valued at USD 7.95 billion in 2025 and is projected to grow to USD 8.50 billion in 2026, with a CAGR of 8.03%, reaching USD 13.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.95 billion
Estimated Year [2026] USD 8.50 billion
Forecast Year [2032] USD 13.65 billion
CAGR (%) 8.03%

Authoritative introduction to granisetron covering clinical mechanism, formulation evolution, and implications for modern antiemetic practice

Granisetron is a selective 5-HT3 receptor antagonist widely used to prevent and treat nausea and vomiting associated with chemotherapy, radiation, and postoperative care. Its clinical utility is grounded in a mechanism that blocks serotonin-mediated emetic signaling in the gastrointestinal tract and central nervous system, making it a mainstay in antiemetic regimens where tolerability and efficacy are critical considerations for patient quality of life. Over time, formulation innovation and shifting clinical guidelines have broadened how clinicians choose to administer granisetron across different care settings, from inpatient infusion suites to outpatient procedures and ambulatory oncology clinics.

Clinical adoption reflects a balance between evidence-based efficacy and practical delivery. Intravenous administration remains essential in acute care settings where rapid onset is required, while oral forms provide flexibility for ambulatory and home-based supportive care. The product lifecycle has been influenced by patent expirations and the entrance of generic formulations, which have altered procurement strategies for hospitals and pharmacies. In parallel, regulatory scrutiny around parenteral preparations and an increased emphasis on cold-chain integrity and sterility assurance have raised the bar for manufacturers and contract formulators.

Looking ahead, granisetron will continue to play an important role in multimodal antiemetic protocols, complemented by emerging agents and supportive therapies. Integration of real-world evidence and patient-reported outcomes is helping clinicians refine dosing and administration practices. As care shifts increasingly toward value-based delivery and outpatient treatment pathways, granisetron's various dosage forms and administration routes position it to remain a versatile component of contemporary antiemetic therapy.

How evolving clinical protocols, manufacturing consolidation, regulatory rigor, and distribution innovation are reshaping the granisetron landscape

The landscape for granisetron is being reshaped by a convergence of clinical, regulatory, and supply-side forces that together are driving transformative shifts in antiemetic care. Advances in formulation science have produced more patient-centric options, including dispersible and oral presentations that reduce barriers to outpatient treatment. At the same time, growing emphasis on multimodal supportive care has encouraged protocol standardization across oncology and perioperative specialties, affecting prescribing patterns and institutional formularies.

Supply chain dynamics and manufacturing consolidation are another powerful driver of change. Greater reliance on specialized sterile injectable capacity and contract manufacturing has heightened sensitivity to production disruptions, prompting organizations to diversify supplier relationships and to adopt more rigorous supplier qualification practices. Regulatory agencies have increased focus on manufacturing quality for parenteral products, elevating compliance costs and influencing which manufacturers can viably supply certain dosage forms.

Technological adoption is altering access and distribution channels. The rise of online pharmacies and integrated hospital distribution systems has expanded procurement choices for providers and patients, while telemedicine and remote care pathways have increased the demand for oral and patient-friendly dosing regimens. These disruptions are not isolated; they interact in compound ways, influencing clinical guideline evolution, payer decision-making, and the competitive positioning of branded versus generic products.

Assessing the operational consequences of 2025 tariff adjustments on pharmaceutical sourcing, supply resilience, and distribution continuity for granisetron

Cumulative policy shifts, tariff adjustments, and trade measures announced through 2025 have introduced new considerations for the global pharmaceutical supply chain that impact granisetron availability and cost structures. Manufacturers and distributors that source active pharmaceutical ingredients or finished dosage forms across borders are evaluating the implications of tariff layering, customs complexity, and potential retaliatory trade measures. These developments are prompting firms to reassess sourcing strategies, contract terms, and inventory buffers to manage exposure to incremental import costs and clearance delays.

As a result, companies are increasingly prioritizing supply chain resilience over minimal inventory models. This has led to a reassessment of regional manufacturing footprints and a stronger emphasis on nearshoring or diversified multisite production to reduce reliance on any single trade route. Procurement teams are renegotiating long-term supplier agreements to include clauses that address tariff pass-through and to secure alternative logistics arrangements. For clinical stakeholders, the immediate consequence is heightened vigilance around continuity of supply, particularly for sterile injectable preparations where manufacturing capacity is concentrated.

From an operational perspective, organizations are investing in customs expertise and trade compliance capabilities to mitigate the administrative burden of heightened tariff complexity. They are also accelerating digitalization of supply chain visibility tools to forecast shipment timing more accurately and to react more promptly to disruptions. Taken together, these measures are stabilizing supply for many stakeholders, but they also increase the fixed costs associated with distribution and inventory management. The landscape through 2025 underscores the need for integrated commercial, regulatory, and procurement strategies to preserve access and manage margin pressures without compromising product quality or patient care.

In-depth segmentation insights revealing how dosage form, clinical application, distribution route, end-user setting, and product type shape granisetron deployment

Segmentation analysis reveals how granisetron's therapeutic and commercial utility is shaped by formulation, clinical application, distribution pathways, end-user settings, and product type. Based on dosage form, the landscape comprises injection options, oral disintegrating tablets, and standard tablets; within injections, clinicians choose between rapid intravenous bolus administrations and controlled intravenous infusions, while tablet formats provide convenience for ambulatory care. Based on application, clinical use is categorized into chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, and radiation-induced nausea and vomiting; within chemotherapy-induced indications, differentiation between the acute phase and the delayed phase informs regimen selection and combination therapy choices.

Distribution channel segmentation distinguishes hospital pharmacies, online pharmacies, and retail pharmacies, each of which serves different procurement and fulfillment models and influences how products are stocked and dispensed. End-user segmentation includes ambulatory surgical centers, clinics, and hospitals, and each setting presents distinct operational needs for dosing flexibility, administration support, and inventory management. Product type segmentation differentiates branded and generic offerings, a dichotomy that shapes procurement behavior, formulary negotiations, and the emphasis on cost containment versus differentiated clinical value.

Understanding these intersecting segments is essential for stakeholders designing market entry strategies, optimizing product portfolios, or refining clinical engagement. Dosage-form choices influence clinical pathways and training needs, application-based segmentation directs evidence-generation priorities, and distribution-end-user dynamics determine logistical investments. Product type considerations ultimately affect pricing strategies, contracting approaches, and promotional focus, making segmentation insights pivotal for targeted commercialization and supply planning.

Regional overview linking healthcare systems, regulatory variability, and distribution infrastructures to differential granisetron access across major geographies

Regional dynamics play a decisive role in how granisetron is manufactured, regulated, and adopted across different healthcare systems. In the Americas, established oncology and perioperative practice patterns favor a mix of injectable and oral options, while procurement tends to balance cost efficiency with continuity of sterile supply. Reimbursement frameworks and hospital formulary processes influence uptake and the relative competitiveness of branded versus generic presentations, and centralized purchasing arrangements can significantly shape tender outcomes.

In Europe, Middle East & Africa, heterogeneity in regulatory pathways and healthcare infrastructure leads to diverse access models. High-income markets in Europe typically emphasize stringent manufacturing quality and demonstrate rapid adaptation to evidence-based guideline changes, whereas certain markets across the broader region may experience distribution friction or slower penetration of novel formulations due to logistical constraints or reimbursement hurdles. Localization of manufacturing and regulatory harmonization initiatives are important trends that affect how companies prioritize regional investments.

In Asia-Pacific, rapid expansion of oncology services and outpatient procedural capacity is driving demand for flexible dosing and user-friendly oral formulations. Robust contract manufacturing ecosystems in several countries support both domestic supply and export-oriented production, while variations in regulatory approval timelines and price sensitivity shape commercialization strategies. Across all regions, demographic shifts, evolving treatment protocols, and investments in healthcare infrastructure will continue to influence how granisetron is positioned clinically and commercially.

Competitive and operational company-level analysis highlighting manufacturing capability, regulatory strength, and distribution partnerships that determine granisetron leadership

Competitive dynamics in the granisetron landscape reflect a balance between incumbent originator companies, generic manufacturers, specialized sterile injectable producers, and distribution-focused organizations. Originator firms driving brand recognition and clinical awareness often invest in evidence generation and clinician education to preserve positioning, whereas generic manufacturers prioritize manufacturing efficiency, regulatory agility, and price competitiveness to capture institutional contracts. Contract manufacturing organizations that specialize in sterile parenteral processing play an outsized role in ensuring supply continuity, particularly for intravenous formulations that require controlled environment production and validated aseptic processes.

Distribution partners and hospital procurement teams exert meaningful influence on where spend is allocated, and strategic alliances between manufacturers and large healthcare systems can streamline formulary placement and shelf stocking. Companies that combine robust manufacturing capacity with strong regulatory track records and responsive supply chains tend to achieve preferred supplier status. Conversely, smaller players can find niches by focusing on patient-friendly oral disintegrating formulations or by providing tailored services such as ready-to-administer syringes and dose-specific presentations that reduce nursing preparation time.

Innovative commercial models, including outcome-based contracting for supportive care therapies and bundled procurement across health networks, are emerging as differentiators. Firms that demonstrate excellence in pharmacovigilance, real-world outcomes collection, and cold-chain logistics will be better positioned to meet the evolving expectations of payers, providers, and patients, and to secure long-term commercial relationships in an increasingly cost-conscious environment.

Practical, cross-functional recommendations to secure manufacturing resilience, clinical differentiation, and distribution alignment for sustained granisetron success

Industry leaders should adopt a multi-dimensional approach that synchronizes clinical, manufacturing, and commercial strategies to secure sustainable advantage. Begin by strengthening manufacturing resilience through multisite qualification, strategic partnerships with specialized sterile injectables providers, and formal contingency plans that address raw-material sourcing and logistics disruptions. Parallel investments in quality systems and regulatory compliance will reduce the risk of supply interruptions and protect product integrity across all dosage forms.

On the commercial front, prioritize evidence generation that addresses unmet clinical questions across key applications, especially differentiation in the acute and delayed phases of chemotherapy-induced nausea and vomiting. Tailor engagement efforts to the needs of hospitals, ambulatory surgical centers, and clinics, and align distribution strategies to the procurement preferences of each channel, including online pharmacies. Develop value propositions that articulate clinical benefits, nursing time savings, and total cost of care implications to support formulary inclusion and favorable contracting outcomes.

Finally, enhance collaboration across procurement, medical affairs, and supply chain teams to ensure alignment between commercial commitments and operational capacity. Build flexible contracting frameworks that account for trade policy volatility and tariff exposure, and invest in digital tools for inventory visibility and demand sensing. By integrating these measures, organizations can protect continuity of care for patients while pursuing growth and differentiation in a competitive antiemetic landscape.

Robust mixed-method research approach combining clinician interviews, regulatory review, pharmacological literature, and supply chain analysis to ensure actionable reliability

The research synthesis underpinning this report integrates primary and secondary evidence, regulatory documentation, pharmacological literature, and stakeholder interviews to ensure robustness and practical relevance. Primary research comprised interviews with clinicians, hospital pharmacists, procurement specialists, and manufacturing experts to capture operational realities, therapeutic preferences, and supply chain constraints. These qualitative insights were triangulated with peer-reviewed clinical studies, product monographs, and publicly available regulatory communications to validate clinical positioning and manufacturing considerations.

Secondary research encompassed a structured review of scientific literature, pharmacovigilance data, guideline recommendations from professional societies, and trade publications with a focus on formulation trends and distribution innovations. Supply chain and trade policy analysis drew on customs and logistics documentation, import-export notices, and industry guidance around tariff implementation to assess potential operational impacts. Throughout the process, findings were validated through iterative consultations with subject-matter experts to ensure that conclusions reflect current practice and foreseeable near-term developments.

Limitations of the methodology include the evolving nature of trade policies and regional regulatory decisions, which can shift rapidly and may alter operational implications. Nevertheless, the mixed-methods approach provides a defensible foundation for strategic decision-making by combining empirical evidence with practitioner experience and domain-specific knowledge.

Conclusive synthesis emphasizing granisetron's enduring clinical relevance coupled with strategic imperatives for manufacturing, distribution, and evidence-driven adoption

Granisetron remains a cornerstone of contemporary antiemetic therapy, supported by a clear mechanism of action and adaptable dosage forms that meet the needs of diverse clinical settings. The interplay between formulation innovation, manufacturing specialization, and distribution channel evolution is creating both opportunities and operational tensions for manufacturers, providers, and distributors. Stakeholders that invest in resilient sterile manufacturing capacity, evidence-generation focused on high-value clinical use cases, and distribution strategies tailored to the preferences of hospitals, clinics, and ambulatory centers will be best positioned to maintain supply continuity and to demonstrate clinical value.

Policy developments, including tariff adjustments and evolving regulatory expectations, demand proactive supply chain management and flexible contracting approaches. Regional nuances in healthcare infrastructure and reimbursement create differentiated pathways to adoption, making localized strategies essential. Overall, granisetron's established clinical role, combined with adaptable commercial approaches and a disciplined focus on manufacturing quality, supports continued relevance in antiemetic care as healthcare systems seek both clinical efficacy and operational efficiency.

In closing, stakeholders should view current dynamics as a prompt to strengthen cross-functional coordination, to accelerate patient-centered formulation development, and to codify supply continuity plans that safeguard patient care while enabling strategic growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Granisetron Market, by Dosage Form

  • 8.1. Injection
    • 8.1.1. Intravenous Bolus
    • 8.1.2. Intravenous Infusion
  • 8.2. Oral Disintegrating Tablet
  • 8.3. Tablet
    • 8.3.1. Standard

9. Granisetron Market, by Product Type

  • 9.1. Branded
  • 9.2. Generic

10. Granisetron Market, by Application

  • 10.1. Chemotherapy-Induced Nausea And Vomiting
    • 10.1.1. Acute Phase
    • 10.1.2. Delayed Phase
  • 10.2. Postoperative Nausea And Vomiting
  • 10.3. Radiation-Induced Nausea And Vomiting

11. Granisetron Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Granisetron Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Granisetron Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Granisetron Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Granisetron Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Granisetron Market

17. China Granisetron Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Cipla Limited
  • 18.6. Dr. Reddy's Laboratories Limited
  • 18.7. F. Hoffmann-La Roche Ltd
  • 18.8. Fresenius Kabi AG
  • 18.9. Glenmark Pharmaceuticals Limited
  • 18.10. Hikma Pharmaceuticals PLC
  • 18.11. Sandoz International GmbH
  • 18.12. Sun Pharmaceutical Industries Limited
  • 18.13. Teva Pharmaceutical Industries Limited
  • 18.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GRANISETRON MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GRANISETRON MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GRANISETRON MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GRANISETRON MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GRANISETRON MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GRANISETRON MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GRANISETRON MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS BOLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS BOLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS BOLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GRANISETRON MARKET SIZE, BY ORAL DISINTEGRATING TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GRANISETRON MARKET SIZE, BY ORAL DISINTEGRATING TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GRANISETRON MARKET SIZE, BY ORAL DISINTEGRATING TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GRANISETRON MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GRANISETRON MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GRANISETRON MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GRANISETRON MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GRANISETRON MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GRANISETRON MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GRANISETRON MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GRANISETRON MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GRANISETRON MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GRANISETRON MARKET SIZE, BY ACUTE PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GRANISETRON MARKET SIZE, BY ACUTE PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GRANISETRON MARKET SIZE, BY ACUTE PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GRANISETRON MARKET SIZE, BY DELAYED PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GRANISETRON MARKET SIZE, BY DELAYED PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GRANISETRON MARKET SIZE, BY DELAYED PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GRANISETRON MARKET SIZE, BY POSTOPERATIVE NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GRANISETRON MARKET SIZE, BY POSTOPERATIVE NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GRANISETRON MARKET SIZE, BY POSTOPERATIVE NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GRANISETRON MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GRANISETRON MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GRANISETRON MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GRANISETRON MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GRANISETRON MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GRANISETRON MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GRANISETRON MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GRANISETRON MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GRANISETRON MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GRANISETRON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GRANISETRON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GRANISETRON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GRANISETRON MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GRANISETRON MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GRANISETRON MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GRANISETRON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS GRANISETRON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GRANISETRON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GCC GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 152. GCC GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 154. GCC GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 157. GCC GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GCC GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 179. G7 GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 181. G7 GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 184. G7 GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. G7 GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. NATO GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 188. NATO GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 190. NATO GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 193. NATO GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. NATO GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)